 Apellis Pharmaceuticals, Inc., a Lousiville, Ky.-based clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, closed a 60m Series E financing. The round was led by Sectoral Asset Management with participation from new investors Sofinnova, Vivo Capital, F-Prime Capital Partners, certain investment funds advised by Clough Capital Partners ... 